---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-26-009999"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2026-09-10T21:24:54+00:00"
generated_at: "2026-09-10T21:26:04.884279+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kala Bio secures exclusive US distribution rights for Virotek ophthalmology genetic testing program

## Summary
- Exclusive 5-year distribution deal with Virotek for ophthalmology genetic testing/screening program in US, effective Sept 3, 2026.
- Profit split 50/50 after Virotek recovers COGS; Kala handles commercial development, Virotek delivery/administration.
- Exclusivity conditioned on Kala meeting milestone by Sept 3, 2027; failure converts to non-exclusive after 30-day cure.
- Kala gets right of first refusal on any sale/license of Virotek's ophthalmology products; term renewable by mutual agreement.

## SEC filing metadata
- accession: 0001829126-26-009999
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2026-09-10T21:24:54+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000182912626009999/0001829126-26-009999-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000182912626009999/kalabio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-26-009999
- JSON: https://secwatch.observer/filing/0001829126-26-009999.json
- Plain text: https://secwatch.observer/filing/0001829126-26-009999.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.